Frontline mRCC: I-O/TKI Treatment RegimensMay 19th 2021
Limitations of current data surrounding the appropriate use of immunotherapy plus a tyrosine kinase inhibitor as frontline therapy for patients with metastatic renal cell carcinoma and current recommendations for selecting an appropriate combination regimen.
Novel Strategies for Intermediate-/Poor-Risk mRCC: Optimizing TherapyApril 28th 2021
Drs Bradley A. McGregor and David F. McDermott comment on best approaches for selecting and optimizing treatment with novel combination regimens to manage patients with intermediate- or poor-risk metastatic renal cell carcinoma.
Lenvatinib-Based Combinations for Intermediate-/Poor-Risk mRCCApril 21st 2021
Thomas E. Hutson, DO, PharmD, of Texas Oncology, reacts to results demonstrated by the CLEAR study of lenvatinib in combination with pembrolizumab or everolimus for the treatment of metastatic renal cell carcinoma and discusses best practices for educating community oncologists on dosing with lenvatinib.
Favorable-Risk mRCC: Combination Regimens Vs Single-Agent TherapyApril 7th 2021
Factors that oncologists need to consider when deciding whether to initiate single-agent therapy or a novel combination regimen as frontline treatment for patients with favorable-risk metastatic renal cell carcinoma.